Welcome to our dedicated page for Arcus Bioscience SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arcus Biosciences, Inc. (NYSE: RCUS) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on oncology and inflammatory and autoimmune diseases, Arcus uses SEC filings to report material clinical, financial and corporate events that can be important for investors analyzing RCUS stock.
Form 8‑K current reports frequently highlight significant developments in Arcus’s pipeline and capital structure. For example, 8‑K filings describe the discontinuation of the Phase 3 STAR‑221 trial and the Phase 2 EDGE‑Gastric study after an interim overall survival analysis showed no benefit for the domvanalimab plus zimberelimab and chemotherapy regimen compared with nivolumab plus chemotherapy. Other 8‑Ks detail updated data from the ARC‑20 Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma, including progression-free survival and response metrics, as well as safety findings.
Filings also cover financing and capital markets transactions. One Form 8‑K outlines an underwriting agreement for a public offering of common stock, including the number of shares sold, pricing and net proceeds. Another 8‑K describes a First Amendment to the company’s Loan and Security Agreement with Hercules Capital and other lenders, which restructures remaining term loan commitments into milestone-based tranches tied to Phase 3 data and potential FDA approval, extends the maturity date and adds performance covenants linked to market capitalization, qualified cash levels and potential net product revenue thresholds.
Investors can also use SEC filings to track collaboration and licensing arrangements, such as disclosures related to Arcus’s long-term collaboration with Gilead Sciences and its option and license agreement with Taiho Pharmaceutical. These documents may reference option exercises, milestone structures and rights to co-develop or commercialize investigational medicines like casdatifan, domvanalimab, zimberelimab and quemliclustat in specific territories.
Stock Titan’s interface surfaces these filings alongside AI-powered summaries that explain the practical implications of each document. Instead of parsing detailed legal language alone, readers can review concise explanations of how a loan amendment changes Arcus’s access to capital, what a trial discontinuation means for a particular program, or how a new data disclosure from a Phase 1/1b or Phase 3 study might influence the company’s development strategy. Real-time updates from EDGAR, combined with these AI insights, help users follow Arcus’s quarterly results, material clinical events, financing decisions and collaboration milestones directly from the underlying SEC record.
RCUS insider filing: A Form 144 notice reports a proposed sale of 53,826 shares of Common Stock tied to a stock option exercise dated 04/23/2026. The filing also records a prior sale of 70,000 shares on 04/08/2026 for $1,579,592.00.
Arcus Biosciences is holding its 2026 Annual Meeting as a fully virtual event on June 11, 2026, at 8:30 a.m. Pacific Time. Stockholders of record as of April 16, 2026, when 125,628,682 common shares were outstanding and entitled to vote, may participate online.
Investors will vote on three items: electing four Class II directors to serve until the 2029 meeting, ratifying Ernst & Young LLP as independent auditor for the 2026 fiscal year, and approving on an advisory basis the compensation of named executive officers. The board recommends voting in favor of all three proposals.
The filing outlines Arcus’s governance structure, including a majority-independent board, a lead independent director, specialized audit, compensation, nominating, and science committees, and policies such as a clawback policy, equity administration policy, and insider trading restrictions.
Arcus Biosciences reported that the Phase 3 STAR-121 study in first-line metastatic non-small cell lung cancer, conducted with Gilead Sciences, has been discontinued for futility based on an Independent Data Monitoring Committee recommendation after a pre-planned futility analysis. Safety was not reassessed in that analysis, and no new safety issues have emerged in ongoing IDMC safety reviews. The related Phase 2 EDGE-Lung study will also be discontinued. The study’s exploratory arm showed zimberelimab plus chemotherapy delivering overall survival consistent with pembrolizumab plus chemotherapy.
Arcus also disclosed that Gilead will allow its broader option period to lapse on July 14, 2026 by not making an option continuation payment. Gilead will lose option rights to early-stage programs such as CCR6, CD89 and CD40L, but retains time-limited options to AB801, AB598, AB102 and an investigational TNF small molecule inhibitor. Arcus continues to hold full rights to casdatifan globally except for rights previously licensed to Taiho in Japan and certain other Asian territories, excluding China.
Arcus Biosciences Inc amended a Schedule 13G/A to report that The Vanguard Group holds 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment on January 12, 2026, after which certain Vanguard subsidiaries report beneficial ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Arcus Biosciences, Inc. reported that Chief Operating Officer Jennifer Jarrett has decided to resign from her role effective March 30, 2026. The company states that her resignation is not due to any disagreement over operations, policies, or practices.
Jarrett has entered into a separation agreement under which she will provide periodic advisory services through June 30, 2026, helping support continuity during the transition. In return, Arcus agreed to extend the period during which she may exercise any vested stock options to twelve months after termination, and the agreement includes a standard release of claims. The final separation agreement will be filed with the company’s next quarterly Form 10-Q.
Arcus Biosciences, Inc. files a shelf registration and establishes an at-the-market equity program to sell up to $200,000,000 of common stock. Sales may occur from time to time after the effective date under an equity distribution agreement with Leerink Partners LLC as sales agent and may be conducted on the New York Stock Exchange or other markets as at-the-market offerings.
As context, Arcus reported 125,294,769 shares outstanding as of December 31, 2025, and its last reported NYSE sale price was $18.85 per share on February 23, 2026.
Arcus Biosciences is a late clinical-stage biopharmaceutical company developing small‑molecule and antibody therapies for cancer and inflammatory and autoimmune diseases. It remains loss‑making and expects significant future losses as it funds extensive research and clinical trials.
The lead oncology asset, casdatifan (HIF‑2α inhibitor), has shown improved efficacy versus belzutifan in late‑line renal cell carcinoma and is in a Phase 3 trial (PEAK‑1) with more Phase 3 work planned. Quemliclustat is in a fully enrolled Phase 3 pancreatic cancer study with results expected in the first half of 2027. TIGIT antibody domvanalimab saw one major gastrointestinal Phase 3 study stopped for futility, but lung cancer trials continue. Arcus is also advancing an oral inflammation pipeline, including MRGPRX2 and TNF programs, with first clinical studies targeted around 2026.
The company relies heavily on strategic partnerships, notably a broad multi‑program collaboration with Gilead that includes options, co‑development, co‑promotion and royalties, and regional licensing with Taiho. It highlights substantial risks around funding needs, clinical and regulatory outcomes, dependence on collaborators and manufacturers, intellectual property protection, competition, cybersecurity and evolving healthcare regulation.
Arcus Biosciences reported fourth-quarter and full-year 2025 results alongside a broad pipeline update. Q4 2025 revenue was $33 million, down from $36 million a year earlier, and the company recorded a net loss of $106 million versus $94 million.
For full-year 2025, total revenue was $247 million and net loss was $353 million. Q4 research and development expenses rose to $121 million, reflecting higher late-stage trial activity, while general and administrative costs were $26 million. Cash, cash equivalents and marketable securities totaled $1.0 billion at December 31, 2025, and Arcus expects funding to last until at least the second half of 2028.
Arcus highlighted strong new data for casdatifan in late-line kidney cancer, with a median progression-free survival of 15.1 months and a confirmed overall response rate of about 45% in the 100mg once-daily cohort. The company is running the Phase 3 PEAK-1 study, planning another Phase 3 trial in first-line metastatic kidney cancer by the end of 2026, and expects at least two casdatifan data readouts in 2026.